Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal Logo BIA

Home page

SHELBY

Self-healing boronic hydrogels for osteoarthritis

Nantes Excellence Trajectory
The SHELBY project was selected as part of the scientific priority Health of the Future - Innovative Biotherapies of the NeXT (Nantes Excellence Trajectory) initiative's call for interdisciplinary research projects. Its objective is to offer innovative therapeutics for osteoarthritis using a new generation of micromoulded hydrogel implants.

The SHELBY project brings together 3 laboratories of the NEXT consortium and 2 associated laboratories to combine their expertise in the life sciences, chemical sciences and engineering sciences in order to offer innovative therapeutics against osteoarthritis.

Osteoarthritis is the most common disabling joint disease.  It is associated with inflammation, joint tissue damage and disabling pain. Current treatments are at best pain relievers but do not prevent joint degeneration. To solve this clinical problem and provide relevant new therapeutic options, intra-articular injections of mesenchymal stem cells (MSCs) derived from bone marrow (BM-MSC) or adipose tissue (AT-MSC) are a promising approach to inhibiting inflammation.

However, although tolerated during injection, "naked" CSM cells have limitations that affect their long-term efficacy: massive cell death during injection and cell leakage outside the joint space.

In this context, the SHELBY project aims to i) develop a new generation of functionalized boronic acid-based hydrogels with self-healing properties, ii) implement micromolding technology to generate injectable carriers, iii) validate the encapsulation of human CSMs in micromolded hydrogels and iv) evaluate the efficacy of encapsulated CSMs to prevent disease progression after intra-articular injection in a surgical-induced murine arthrosis model.
The SHELBY project aims to encapsulate CSMs in cytoprotective hydrogels to provide CSMs with a favourable microenvironment capable of supporting their viability and biological activities.

illustration-shelby

 

The BIA Unit is responsible for the design of boronic acid-based micromouldings using a soft lithography technique recently developed by the Nanostructured Assemblies (NANO) team.

  • Duration of the project: 1 year,  with possible extension to 4 years, from September 2018.
  • Academic partners:
    • Inserm U1229- Regenerative Medicine and Skeleton, RMeS 
    • CEISAM CNRS 6230
    • INRA BIA UR1268
  • Associated academic partners:
    • UMR CNRS 6283, Institut des Molécules et Matériaux du Mans (IMMM)
    • Inserm U1183, Institut de Médecine Régénératrice et Biothérapies (IRMB)
  • Budget: 455 000 € incl.  an amount of subventions of 140 000 €